Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study, to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Repeated Doses of DS-2330b Alone and When Co-administered With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT03305471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03305471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study, to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Repeated Doses of DS-2330b Alone and When Co-administered With Sevelamer in Patients on Chronic Hemodialysis
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2017
Completion date
January 3, 2019
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia